Class I Recall of Fresenius Kabi Volumat MC Agilia Infusion Pump and Vigilant Agilia Drug Library

PUBLISHED: Aug 12, 2019
Relevant to: All Healthcare Organizations

Fresenius Kabi is recalling their Volumat MC Agilia Infusion Pump and Vigilant Agilia Drug Library due to a "Low Priority" "Keep Vein Open (KVO), End of Infusion" alarm and multiple software errors. According to the recall notice, when enabled, the "Keep Vein Open (KVO), End of Infusion" alarm triggers when the infusion is complete. This results in the therapeutic rate of a medication changing to a non-therapeutic rate, as defined by the KVO rate. KVO alarms should be high priority. If a health care provider fails to respond to a "KVO, End of Infusion" alarm for a critical medication, a delay in care and/or under-infusion of medication can take place, which may lead to death or serious injury because the patient will be receiving a non-therapeutic rate of medication.

Fresenius Kabi will change their "Keep Vein Open (KVO), End of Infusion" alarm from a "low priority" to a "high priority" alarm to ensure the health care provider knows the infusion has completed. There has been one death reported outside of the United States related to a norepinephrine infusion where a health care provider did not adjust the "Volume to be Infused" after changing the drug bag and then did not notice the pump's "low priority" "KVO, End of Infusion" alarm. No other injuries have been reported in the rest of the world or in the United States.

Fresenius has also identified four software errors occurring with both the Volumat MC Agilia Infusion System and Vigilant Drug Library that may cause over-infusion or under-infusion of fluids/medications. These software errors could cause serious patient harm or death. There have been zero injuries and 14 complaints reported related to these software errors. See the recall notice for a complete list of those software errors.

Fresenius Kabi sent an "Urgent Device Recall" letter to all affected customers on June 21, 2019. They issued an updated letter on July 26, 2019 to clarify that for the "Incorrect VTBI Calculations for Programmed Bolus Under Specific Conditions" software issue, flow rates equal to 9.9ml per hour (not only flow rates less than 9.9m per hour) are also affected. The letters included specific actions that users of these devices should take to prevent patient harm until Fresenius Kabi can make corrections on site.

As the company works to make corrections, the software for both devices will be upgraded in two phases: July 2019 and September 2019. Customers will be contacted by a company representative to schedule appointments to make the necessary software updates.

Health care professionals and consumers may report adverse reactions or quality problems they experience using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

Want to read the full alert and receive alert emails?

Browse Additional Alerts